Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.

Abstract:

PURPOSE:This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS:This cross-sectional study included 192 CA and 173 NHW female breast cancer survivors (stages 0-III, diagnosed between 2006 and 2012) recruited from two California cancer registries, who had completed primary treatment. Patient-reported data on treatment-related symptoms and potential covariates were collected via telephone interviews. Dietary data were ascertained by mailed questionnaires. The outcomes evaluated were menopausal symptoms (hot flashes, night sweats, vaginal dryness, vaginal discharge), joint problems, fatigue, hair thinning/loss, and memory problems. Associations between soy and cruciferous vegetables and symptoms were assessed using logistic regression. Analyses were further stratified by race/ethnicity and endocrine therapy usage (non-user, tamoxifen, aromatase inhibitors). RESULTS:Soy food and cruciferous vegetable intake ranged from no intake to 431 and 865 g/day, respectively, and was higher in CA survivors. Higher soy food intake was associated with lower odds of menopausal symptoms (≥ 24.0 vs. 0 g/day, OR 0.51, 95% CI 0.25, 1.03), and fatigue (≥ 24.0 vs. 0 g/day, OR 0.43, 95% CI 0.22, 0.84). However, when stratified by race/ethnicity, associations were statistically significant in NHW survivors only. Compared with low intake, higher cruciferous vegetable intake was associated with lower odds of experiencing menopausal symptoms (≥ 70.8 vs. < 33.0 g/day, OR 0.50, 95% CI 0.25, 0.97) in the overall population. CONCLUSIONS:In this population of breast cancer survivors, higher soy and cruciferous vegetable intake was associated with less treatment-related menopausal symptoms and fatigue.

authors

Nomura SJO,Hwang YT,Gomez SL,Fung TT,Yeh SL,Dash C,Allen L,Philips S,Hilakivi-Clarke L,Zheng YL,Wang JH

doi

10.1007/s10549-017-4578-9

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

467-479

issue

2

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-017-4578-9

journal_volume

168

pub_type

杂志文章
  • Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.

    abstract::Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. However, the immunocompetence of TIL and the possibility to consistentl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/A:1024938215782

    authors: Kass R,Bellone S,Palmieri M,Canè S,Bignotti E,Henry-Tillman R,Hutchins L,Cannon MJ,Klimberg S,Santin AD

    更新日期:2003-08-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract::The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014815112078

    authors: Hayden LJ,Satre MA

    更新日期:2002-03-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract::The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0080-8

    authors: Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期:2009-05-01 00:00:00

  • Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.

    abstract::MicroRNAs play a role in breast cancer development and progression by post-transcriptional repression of the expression of important genes, such as the tumor suppressor gene phosphatase and tensin homolog (PTEN). The focus of the current study was to examine the diagnostic potential of circulating cell-free microRNAs ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-1988-6

    authors: Schwarzenbach H,Milde-Langosch K,Steinbach B,Müller V,Pantel K

    更新日期:2012-08-01 00:00:00

  • PALB2 mutations in German and Russian patients with bilateral breast cancer.

    abstract::Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Patients with bilateral breast cancer constitute a valuable group for ge...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1290-4

    authors: Bogdanova N,Sokolenko AP,Iyevleva AG,Abysheva SN,Blaut M,Bremer M,Christiansen H,Rave-Fränk M,Dörk T,Imyanitov EN

    更新日期:2011-04-01 00:00:00

  • Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

    abstract::To assess the impact of patient-provider communication on adherence to tamoxifen (TAM) and aromatase inhibitors (AIs) 36 months after breast cancer (BC) diagnosis in a low-income population of women. California statewide surveys were conducted among 921 low-income women with BC at 6, 18, and 36 months after BC diagnos...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2387-8

    authors: Liu Y,Malin JL,Diamant AL,Thind A,Maly RC

    更新日期:2013-02-01 00:00:00

  • Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.

    abstract::MCF-7 cells, a metastatic human breast carcinoma line, caused dose-dependent platelet aggregation in heparinized human platelet-rich plasma (PRP). MCF-7 tumor cell-induced platelet aggregation (TCIPA) was almost blocked by apyrase (0.5 U/ml) and completely inhibited by hirudin (5 U/ml). This TCIPA was unaffected by cy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665947

    authors: Chiang HS,Swaim MW,Huang TF

    更新日期:1995-03-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract::Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3608-8

    authors: Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期:2015-11-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract::This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1332-y

    authors: Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期:2011-04-01 00:00:00

  • Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.

    abstract:BACKGROUND:Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Though significant improvements of progression-free survival (PFS) for CDK4/6 inhibitor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-020-05528-2

    authors: Li J,Fu F,Yu L,Huang M,Lin Y,Mei Q,Lv J,Wang C

    更新日期:2020-02-01 00:00:00

  • HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

    abstract::This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology se...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1029-2

    authors: Wilking U,Karlsson E,Skoog L,Hatschek T,Lidbrink E,Elmberger G,Johansson H,Lindström L,Bergh J

    更新日期:2011-01-01 00:00:00

  • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

    abstract:AIMS:To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status. METHODS:2227 recently operated cases in one centre were retrieved from the Multidisciplinary Breast Centre database and stratified accor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9914-7

    authors: Van Calster B,Vanden Bempt I,Drijkoningen M,Pochet N,Cheng J,Van Huffel S,Hendrickx W,Decock J,Huang HJ,Leunen K,Amant F,Berteloot P,Paridaens R,Wildiers H,Van Limbergen E,Weltens C,Timmerman D,Van Gorp T,Smeets A,V

    更新日期:2009-01-01 00:00:00

  • Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

    abstract::Epidermal growth factor receptor (EGFr) levels were analyzed in 140 primary breast cancer specimens by immunohistochemical assay (ICA), competitive binding assay (BA), or enzyme immunoassay (EIA). Thirty-nine of 118 specimens (33.1%) were scored as positive by ICA, 30 of 116 (25.9%; cut-off level 10 fmol/mg protein) b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666582

    authors: Iwase H,Kobayashi S,Itoh Y,Kuzushima T,Yamashita H,Iwata H,Naito A,Yamashita T,Itoh K,Masaoka A

    更新日期:1993-12-01 00:00:00

  • Endocan as a prognostic biomarker of triple-negative breast cancer.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC) has aggressive characteristics and fewer treatment options than other subtypes. The purpose of this study was to explore prognostic biomarkers for TNBC that can be easily detected from the blood samples. METHODS:MDA-MB-231 and MDA-MB-231BR, a brain metastatic variant of the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4057-8

    authors: Sagara A,Igarashi K,Otsuka M,Kodama A,Yamashita M,Sugiura R,Karasawa T,Arakawa K,Narita M,Kuzumaki N,Narita M,Kato Y

    更新日期:2017-01-01 00:00:00

  • Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins.

    abstract::The complexity of breast cancer biology makes it challenging to analyze large datasets of clinicopathologic and molecular attributes, toward identifying the key prognostic features and producing systems capable of predicting which patients are likely to relapse. We applied machine-learning techniques to analyze a set ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0557-0

    authors: Asgarian N,Hu X,Aktary Z,Chapman KA,Lam L,Chibbar R,Mackey J,Greiner R,Pasdar M

    更新日期:2010-06-01 00:00:00

  • Availability of prior mammograms affects incomplete report rates in mobile screening mammography.

    abstract:PURPOSE:Mobile mammography can improve access to screening mammography in rural areas and underserved populations. We evaluated the frequency of incomplete reports in mobile mammography screening and the relationships between prior mammograms and recall rates. METHODS:The frequency of incomplete mammogram reports, the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4861-4

    authors: Roubidoux MA,Shih-Pei Wu P,Nolte ELR,Begay JA,Joe AI

    更新日期:2018-10-01 00:00:00

  • Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.

    abstract::Previous studies showing the presence of antibodies against tumor-associated antigens in healthy individuals suggest that antibody-dependent cell cytotoxicity (ADCC) might play a role in the development of breast cancer. We hypothesized that functional polymorphisms in fragment c gamma receptor (FcgR) genes were assoc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-010-1109-3

    authors: Iwasaki M,Shimada N,Kasuga Y,Yokoyama S,Onuma H,Nishimura H,Kusama R,Hamada GS,Nishimoto IN,Iyeyasu H,Motola J Jr,Laginha FM,Anzai R,Tsugane S

    更新日期:2011-04-01 00:00:00

  • Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells.

    abstract::Manganese superoxide dismutase (MnSOD) is known to play a role in cancer. MnSOD exerts a tumor suppressive effect in estrogen-dependent human breast cancer cells. In the present study we investigated the in vitro role of MnSOD in the growth of some aggressive and highly metastatic estrogen-independent breast cancer ce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9597-5

    authors: Kattan Z,Minig V,Leroy P,Dauça M,Becuwe P

    更新日期:2008-03-01 00:00:00

  • Predictive factors of nipple involvement in breast cancer: a systematic review and meta-analysis.

    abstract::Nipple-sparing mastectomy (NSM) provides a cosmetic and psychological benefit for patients, but concerns on nipple involvement (NI) of tumor continue to persist. Several studies have reported factors for predicting NI, but the results were inconsistent and uncomprehensive, making patient selection difficult. The aim o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-015-3385-4

    authors: Zhang H,Li Y,Moran MS,Haffty BG,Yang Q

    更新日期:2015-06-01 00:00:00

  • The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40.

    abstract::Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012942910375

    authors: Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

    更新日期:2001-11-01 00:00:00

  • Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.

    abstract::A potential advantage of primary over adjuvant chemotherapy in breast cancer survival had been proposed on theoretical grounds. In 1994, early results of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy for operable breast cancer in 390 premenopausal patients had shown significant improvement in s...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1006339918798

    authors: Broët P,Scholl SM,de la Rochefordière A,Fourquet A,Moreau T,De Rycke Y,Asselain B,Pouillart P

    更新日期:1999-11-01 00:00:00

  • Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

    abstract::Local formation of estradiol in human breast tumors could provide a more important source of estrogen than is delivered from plasma. Prior studies have suggested that estrone is primarily synthesized from estrone sulfate. The enzyme 17 beta-hydroxysteroid dehydrogenase (HSD) would be required to convert estrone to est...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01886734

    authors: Santner SJ,Leszczynski D,Wright C,Manni A,Feil PD,Santen RJ

    更新日期:1986-01-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract:PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05488-2

    authors: Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期:2020-02-01 00:00:00

  • Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.

    abstract::The positive effects of tamoxifen (TAM) on breast cancer recurrence and survival as well as on overall mortality have led to its use as the predominant adjuvant therapy among women with breast cancer. However, the association of TAM intake with undesirable side effects has been reported in numerous studies. This analy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000021050.92539.b0

    authors: Gallicchio L,Lord G,Tkaczuk K,Danton M,Lewis LM,Lim CK,Flaws JA

    更新日期:2004-05-01 00:00:00

  • Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

    abstract::Germline mutations in the BRCA1/2 genes account for the majority of hereditary breast ovarian cancer (HBOC). Identification of causal mutations may have significant impact on clinical management of such families. Despite high mutation detection rate, many HBOC cases remain without identified cause. These cases warrant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1325-x

    authors: Konecny M,Milly M,Zavodna K,Weismanova E,Gregorova J,Mlkva I,Ilencikova D,Kausitz J,Bartosova Z

    更新日期:2011-02-01 00:00:00

  • Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.

    abstract:PURPOSE:Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS:We conduc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06079-2

    authors: Zhi WI,Baser RE,Kwon A,Chen C,Li SQ,Piulson L,Seluzicki C,Panageas KS,Harte SE,Mao JJ,Bao T

    更新日期:2021-01-28 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract::Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-013-2611-1

    authors: Russo AL,Taghian AG

    更新日期:2013-07-01 00:00:00

  • Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.

    abstract::Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of c...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01806692

    authors: Casper ES,Guidera CA,Bosl GJ,Hakes TB,Kaufman RJ,Shurgot B,Kinne DW

    更新日期:1987-01-01 00:00:00

  • Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.

    abstract::Genome-Wide Association Studies have identified several loci associated with breast cancer (BC) in populations of different ethnic origins. One of the strongest associations was found in the FGFR2 gene, and MAP3K1 has been proposed as a low-penetrance BC risk factor. In this study, we evaluated the associations among ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2359-z

    authors: Jara L,Gonzalez-Hormazabal P,Cerceño K,Di Capua GA,Reyes JM,Blanco R,Bravo T,Peralta O,Gomez F,Waugh E,Margarit S,Ibañez G,Romero C,Pakomio J,Roizen G

    更新日期:2013-01-01 00:00:00